Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches
Therapeutic options for patients with more severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is accumulating evidence that anti-tumor-necrosis-factor (anti-TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis and psoriatic arthritis. The major anti-TNF-α agents currently available, infliximab (Remicade®) and etanercept (Enbrel®), are approved for the treatment of rheumatoid arthritis (RA) in many countries. In ankylosing spondylitis there is an unmet medical need, since there are almost no disease-modifying antirheumatic drugs (DMARDs) available for severely affected patients, especially those with spinal manifestations. Judging from recent data from more than 300 patients with SpA, anti-TNF therapy seems to be even more effective in SpA than in rheumatoid arthritis. However, it remains to be shown whether patients benefit from long-term treatment, whether radiological progression and ankylosis can be stopped and whether long-term biologic therapy is safe.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[
"009:25"
]
|
| contactPoint |
{
"fn": "NIH",
"@type": "vcard:Contact",
"hasEmail": "mailto:info@nih.gov"
}
|
| description | Therapeutic options for patients with more severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is accumulating evidence that anti-tumor-necrosis-factor (anti-TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis and psoriatic arthritis. The major anti-TNF-α agents currently available, infliximab (Remicade®) and etanercept (Enbrel®), are approved for the treatment of rheumatoid arthritis (RA) in many countries. In ankylosing spondylitis there is an unmet medical need, since there are almost no disease-modifying antirheumatic drugs (DMARDs) available for severely affected patients, especially those with spinal manifestations. Judging from recent data from more than 300 patients with SpA, anti-TNF therapy seems to be even more effective in SpA than in rheumatoid arthritis. However, it remains to be shown whether patients benefit from long-term treatment, whether radiological progression and ankylosis can be stopped and whether long-term biologic therapy is safe. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Official Government Data Source",
"mediaType": "text/html",
"description": "Visit the original government dataset for complete information, documentation, and data access.",
"downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128942/"
}
]
|
| identifier | https://healthdata.gov/api/views/s5h7-wgmj |
| issued | 2025-07-14 |
| keyword |
[
"ankylosing-spondylitis",
"anti-tnf-therapy",
"nih",
"psoriatic-arthritis",
"spondyloarthritis"
]
|
| landingPage | https://healthdata.gov/d/s5h7-wgmj |
| modified | 2025-09-06 |
| programCode |
[
"009:035"
]
|
| publisher |
{
"name": "National Institutes of Health",
"@type": "org:Organization"
}
|
| theme |
[
"NIH"
]
|
| title | Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches |
